latest news releases from the newsroom
Progen Pharmaceuticals Limited
Progen Receives NASDAQ Deficiency Notice
BRISBANE, Australia, Sept. 8, 2008 (GLOBE NEWSWIRE) -- Progen Pharmaceuticals Limited (ASX:PGL) (Nasdaq:PGLA) today announced that it received a letter dated 4 September 2008, from the Nasdaq Stock Market notifying the company that for the last 30 consecutive business days prior to 4 September, the bid price for the Company's ordinary shares has closed below the minimum $US1.00 per share requirement for continued inclusion under Nasdaq Marketplace Rule 4320(e)(2)(E)(ii) (the "Rule").
CombiMatrix to Hold Conference Call to Discuss Recent Findings Utilizing Its HemeScan Test for Chronic Lymphocytic Leukemia Patients
MUKILTEO, Wash., Sept. 8, 2008 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) will hold a conference call to discuss recent findings demonstrating the value of its HemeScan(tm) test for Leukemia patients. Company management, including Dr. Mansoor Mohammed, President and CEO of Combimatrix Molecular Diagnostics and Dr. Shelly Gunn, Medical Director of Combimatrix Molecular Diagnostics, will host this call and will make a short presentation, followed by Q&A. Combimatrix Molecular Diagnostics is a wholly owned subsidiary of CombiMatrix Corporation.